Skip to main content
. 2011 Dec 16;1(1):5. doi: 10.1007/s13554-011-0004-8

Table 6.

Incidence of anti-growth hormone (GH) antibodies* during the first 18 months of treatment and overall.

Baseline-9 months 9–18 months Odds ratio
n % n %
AQ study† (n=44) 0 0.0 1 2.3
Lyo study (n=50) 0 0.0 0 0.0
Spanish study (n=69) 2 2.9 0 0.0 0.00

*Presence of an anti-GH antibody is defined by at least two consecutive positive test results.

†Group B of AQ study.